Scientists from two universities in Ontario, Canada reported progress on their efforts to release the world’s first hand-held home test kit designed to screen for cancer.
A home-based screening kit for different kinds of cancers would be game-changing in the quest for more proactive health monitoring. To this end, researchers from McMaster and Brock universities are developing a device that lets patients monitor their own blood for the unique biomarkers of prostate cancer.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels.
Normally, when patients submit blood samples to a lab, doctors will look for specific biomarkers that indicate signs that a cancer may be present. These biomarkers are chemicals within the body that can indicate either normal or abnormal conditions if they are over- or under-represented in a blood sample.
The device developed at McMaster and Brock allows users to mix a droplet of their blood into a vial containing a reactive liquid prepared by the lab. Users then place that mixture onto a strip and insert it into the device’s reader system. Then, after only a few minutes, the device measures for the presence of PSA and informs the user about the degree to which cancer may be present.
If users can complete a test like this from the comfort of their own home—avoiding a trip to the doctor’s office—more people could be checking their own health, and possibly detect disease at an earlier stage. It would also cut down on the number of times patients need to leave home to provide blood samples, once they’ve been diagnose.
Leyla Soleymani, a biomedical engineer at McMaster, and Canada Research Chair in Miniaturized Biomedical Devices, led the team responsible for the hardware of the device, including the chip that reads the sample.
“This is another step toward truly personalized medicine,” she said in a McMaster’s statement. “We’re getting away from centralized, lab-based equipment for this kind of testing.”
Researchers also point out that this technology can be readily adapted to measure other markers, depending on the form of cancer or other chronic disease. The device would also allow patients to continue to monitor their health after treatment.
More testing beyond their proof-of-concept study will be required before the team can pursue commercial applications. But the development would be a large leap forward increasing the accessibility of proactive, personalized, home-based health monitoring.